1. Introduction
1.1. Origin and epidemiology
Dengue virus (DENV) is a member of the
1.2. Transmission
The transmission of DENV can only occur by the bite of an infected female mosquito, the
The tiger mosquito
Because there is no vaccine available, the only efficient way to prevent DENV infection is eradication of the mosquito. In the 1950s and 1960s there was a successful vector control program in the USA organized by the Pan American Health Organization. They eradicated the mosquito from 19 countries. Unfortunately, the vector control program was stopped in 1972 because the government thought that DENV was not important anymore [2,4]. This resulted in a re-emergence of the mosquito and DENV infections in the USA. Both demographic and ecological changes contributed to the world wide spread of DENV infections.
Very recently, another approach to attack the vector has been documented [8,9]. There was a mosquito made resistant to DENV infection after trans infection with the endosymbiont
1.3. Pathogenesis
Although DENV infections have a high prevalence, the pathogenesis of the disease is not well understood. The disease spectrum can range from an asymptomatic or flu like illness to a lethal disease. After a bite of an infected mosquito, there is an incubation period of 3 to 8 days. Then there is on acute onset of fever ( ≥ 39°C) accompanied by nonspecific symptoms like severe headache, nausea, vomiting, muscle and joint pain (dengue fever). Clinical findings alone are not helpful to distinguish dengue fever from other febrile illnesses such as malaria or measles. Half of the infected patients report a rash and is most commonly seen on the trunk and the insides of arms and thighs. Skin hemorrhages, including petechiae and purpura, are very common. Liver enzyme levels of alanine aminotransferase and aspartate aminotransferase can be elevated. Dengue fever is generally self-limiting and is rarely fatal [5,10,11].
The disease can escalate into dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). DHF is primarily a children’s disease and is characterized as an acute febrile illness with thrombocytopenia (≤ 100,000 cells/mm3). This results in an increased vascular permeability and plasma leakage from the blood vessels into the tissue. Plasma leakage has been documented by an increased hematocrit and a progressive decrease in platelet count. Petechiae and subcutaneous bleedings are very common [12].
DSS is defined when the plasma leakage becomes critical resulting in circulatory failure, weak pulse and hypotension. Plasma volume studies have shown a reduction of more than 20% in severe cases. A progressively decreasing platelet count, a rising hematocrit, sustained abdominal pain, persistent vomiting, restlessness and lethargy may be all signs for DSS. Prevention of shock can only be established after volume replacement with intravenous fluids [5,11]. When experienced clinicians and nursing staff are available in endemic areas, the case fatality rate is < 1%.
DHF and DSS occur during a secondary infection with a heterologous serotype. The first infection with one of the four serotypes provides lifelong immunity to the homologous virus. During a second infection with a heterologous serotype, non-neutralizing IgG antibodies can enhance disease severity. This phenomenon is called antibody-dependent enhancement (ADE). The pre-existing non-neutralizing heterotypic antibodies can form a complex with DENV and enhance the access to Fc-receptor bearing cells such as monocytes and macrophages [13,14] (Figure 3).
This will lead to an increase in viral load and a more severe disease. These non-neutralizing antibodies can cross-react with all four virus serotypes, as well as with other flaviviruses. This phenomenon explains why young infants born to dengue immune mothers often experience a more severe disease due to transplacental transfer of DENV-specific antibodies [15]. Another approach to assist this phenomenon is the observation of increased viremia in non-human primates which received passive immunization with antibodies against DENV [16].
A second mechanism to explain ADE of flaviviruses is the involvement of the complement system. It has been shown that monoclonal antibodies against complement receptor 3 inhibit ADE of West Nile virus
2. DENV entry
2.1. Entry process
The infectious entry of DENV into its target cells, mainly dendritic cells [17], monocytes and macrophages, is mediated by the viral envelope glycoprotein E via receptor-mediated endocytosis [18]. The E-glycoprotein is the major component (53 kDa) of the virion surface and is arranged as 90 homodimers in mature virions [19]. Recent reports demonstrated also that DENV enters its host cell via clathrin-mediated endocytosis [20,21], as observed with other types of flaviviruses [22,23]. Evidence for flavivirus entry via this pathway is based on the use of inhibitors of clathrin-mediated uptake, such as chlorpromazine. However, DENV entry via a non-classical endocytic pathway independent from clathrin has also been described [24]. It seems that the entry pathway chosen by DENV is highly dependent on the cell type and viral strain. In case of the classical endocytic pathway, there is an uptake of the receptor-bound virus by clathrin coated vesicles. These vesicles fuse with early endosomes to deliver the viral RNA into the cytoplasm. The E-protein responds to the reduced pH of the endosome with a large conformational rearrangement [25,26]. The low pH triggers dissociation of the E-homodimer, which then leads to the insertion of the fusion peptide into the target cell membrane forming a bridge between the virus and the host. Next, a stable trimer of the E-protein is folded into a hairpin-like structure and forces the target membrane to bend towards the viral membrane and eventually fusion takes place [25,27,28]. The fusion results in the release of viral RNA into the cytoplasm for initiation of replication and translation (Figure 4).
2.2. The DENV envelope
The DENV E-glycoprotein induces protective immunity and flavivirus serological classification is based on its antigenic variation. During replication the virion assumes three conformational states: the immature, mature and fusion-activated form. In the immature state, the E-protein is arranged as a heterodimer and generates a “spiky” surface because the premembrane protein (prM) covers the fusion peptide. In the Golgi apparatus, the virion maturates after a rearrangement of the E-protein. The E-heterodimer transforms to an E-homodimer and results in a “smoothy” virion surface. After a furin cleavage of the prM to pr and M, the virion is fully maturated and can be released from the host cell. Upon fusion, the low endosomal pH triggers the rearrangement of the E-homodimer into a trimer [29].
The E-protein monomer is composed out of β-barrels organized in three structural domains (Figure 5).
The central domain I contains the aminoterminus and contains two disulfide bridges. Domain II is an extended finger-like domain that bears the fusion peptide and stabilizes the dimer. This sequence contains three disulfide bridges and is rich in glycine. Between domain I and domain II is a binding pocket that can interact with a hydrophobic ligand, the detergent β-N-octyl-glucoside. This pocket is an important target for antiviral therapy because mutations in this region can alter virulence and the pH necessary for the induction of conformational changes. The immunoglobulin-like domain III contains the receptor binding motif, the C-terminal domain and one disulfide bond [30,31]. Monoclonal antibodies recognizing domain III are the most efficient of blocking DENV [32,33] and this domain is therefore an interesting target for antiviral therapy.
Because dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) (See 1.3.1) is identified as an important receptor for DENV in primary DC in the skin and DC-SIGN recognizes high-mannose sugars, carbohydrates present on the E-protein of DENV could be important for viral attachment. The E-protein has two potential glycosylation sites: asparagines 67 (Asn67) and Asn153. Glycosylation at Asn153 is conserved in flaviviruses, with the exception of Kunjin virus, a subtype of West Nile virus [34] and is located near the fusion peptide in domain II [30,31] (Figure 5). Glycosylation at Asn67 is unique for DENV [31].
3. Role of DC-SIGN in DENV infection
Prior to fusion, DENV needs to attach to specific cellular receptors. Because DENV can infect a variety of different cell types isolated from different hosts (human, insect, monkey and even hamster), the virus must interact with a wide variety of cellular receptors. In the last decade, several candidate attachment factor/receptors are identified. DC-SIGN is described as the most important human cellular receptor for DENV.
Since 1977, monocytes are considered to be permissive for DENV infection [35]. More recent, phenotyping of peripheral blood mononuclear cells (PBMCs) from pediatric DF and DHF cases resulted in the identification of monocytes as DENV target cells [36].
First, it was believed that monocytes are important during secondary DENV infections during the ADE process, because of their Fc-receptor expression. The complex formed between the non-neutralizing antibody and the virus can bind to Fc-receptors and enhance infection in neighboring susceptible cells [14,18,37]. However,
More detailed observation of the natural DENV infection, changes the idea of monocytes being the first target cells. Following intradermal injection of DENV-2 in mice, representing the bite of an infected mosquito, DENV occurs to replicate in the skin [38]. The primary DENV target cells in the skin are believed to be immature dendritic cells (DC) or Langerhans cells [17,39-41]. Immature DC are very efficient in capturing pathogens whereas mature DC are relatively resistant to infection. The search for cellular receptors responsible for DENV capture leads to the identification of cell-surface C-type lectin DC-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN; CD209) [42-45]. DC-SIGN is mainly expressed by immature DC, but also alveolar macrophages and interstitial DC in the lungs, intestine, placenta and in lymph nodes express DC-SIGN [46]. DC-SIGN is a tetrameric transmembrane receptor and is a member of the calcium-dependent C-type lectin family. The receptor is composed of four domains: a cytoplasmic domain responsible for signaling and internalization due to the presence of a dileucine motif, a transmembrane domain, seven to eight extracellular neck repeats implicated in the tetramerization of DC-SIGN and a carbohydrate recognition domain (CRD) (Figure 6) [47].
Alen
Thus, the CRD of DC-SIGN recognizes high-mannose N-glycans and also fucose-containing blood group antigens [48,49]. Importantly, DC-SIGN can bind a variety of pathogens like human immunodeficiency virus (HIV) [50], hepatitis C virus (HCV) [51], ebola virus [52] and several bacteria, parasites and yeasts [46]. Many of these pathogens have developed strategies to manipulate DC-SIGN signaling to escape from an immune response [46]. Following antigen capture in the periphery, DC maturate by up regulation of the co-stimulatory molecules and down regulation of DC-SIGN. By the interaction with ICAM-2 on the vascular endothelial cells, DC can migrate to secondary lymphoid organs [53]. Next, the activated DC interact with ICAM-3 on naïve T-cells. This results in the stimulation of the T-cells and subsequently in the production of cytokines and chemokines [54]. Inhibition of the initial interaction between DENV and DC could prevent an immune response. DC-SIGN could be considered as a target for antiviral therapy by interrupting the viral entry process. But caution must be taken into account as the DC-SIGN receptor has also an important role in the activation of protective immune responses instead of promoting the viral dissemination. However, several DC-SIGN antagonists have been developed such as small interfering RNAs (siRNA) silencing DC-SIGN expression [55], specific anti-DC-SIGN antibodies [56] and glycomimetics interacting with DC-SIGN [57]. The
Besides DC, macrophages play a key role in the immune pathogenesis of DENV infection as a source of immune modulatory cytokines [58]. Recently, Miller
Another C-type lectin, CLEC5A (C-type lectin domain family 5, member A) expressed by human macrophages can also interact with DENV and acts as a signaling receptor for the release of proinflammatory cytokines [64]. However, whereas the DC-SIGN-DENV interaction is calcium-dependent, CLEC5A binding to its ligand is not dependent on calcium. Mannan and fucose can inhibit the interaction between CLEC5A and DENV, indicating that the interaction is carbohydrate-dependent [64]. However, a glycan array demonstrated no binding signal between CLEC5A and N-glycans of mammals or insects [65]. The molecular interaction between CLEC5A and DENV remains to be elucidated.
Immune cells, in particular dendritic cells, are the most relevant cells in the discovery of specific antiviral drugs against dengue virus, but the isolation of these cells and the characterization is unfortunately labour intensive and time consuming.
Liver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN) is a DC-SIGN related transmembrane C-type lectin expressed on endothelial cells in liver, lymph nodes and placenta [66,67]. Similar to DC-SIGN, L-SIGN is a calcium-dependent carbohydrate-binding protein and can interact with HIV [67], HCV [51], Ebola virus [52], West Nile virus [68] and DENV [45]. Zellweger
4. Antiviral therapy
At present, diagnosis of dengue virus infection is largely clinical, treatment is supportive through hydration and disease control is limited by eradication of the mosquito. Many efforts have been made in the search for an effective vaccine, but the lack of a suitable animal model, the need for a high immunogenicity vaccine and a low reactogenicity are posing huge challenges in the dengue vaccine development [7,72]. There are five conditions for a dengue vaccine to be effective: (i) the vaccine needs to be protective against all four serotypes without reactogenicity, because of the risk of ADE, (ii) it has to be safe for children, because severe dengue virus infections often affects young children, (iii) the vaccine has to be economical with minimal or no repeat immunizations, because dengue is endemic in many developing countries, (iv) the induction of a long-lasting protective immune response is necessary and finally (v) the vaccine may not infect mosquitoes by the oral route [7,73].
As there is no vaccine available until now, the search for antiviral products is imperative. The traditional antiviral approach often attacks viral enzymes, such as proteases and polymerases [74,75]. Because human cells lack RNA-dependent polymerase, this enzyme is very attractive as antiviral target without cytotoxicity issues. Nucleoside analogues and non-nucleoside compounds have previously been shown to be very effective in anti-HIV therapy and anti-hepatitis B virus therapy. The protease activity is required for polyprotein processing which is necessary for the assembly of the viral replication complex. Thereby, the protease is an interesting target for antiviral therapy. However, the host cellular system has similar protease activities thus cytotoxic effects form a major recurrent problem. Very recently, many efforts have been made in the development of polymerase and protease inhibitors of DENV, but until today, any antiviral product has reached clinical trials. This chapter is focusing on a different step in the virus replication cycle, namely, the viral entry process. In the past few years, progression has been made in unraveling the host cell pathways upon DENV infection. It is proposed that viral epitopes on the surface of DENV can trigger cellular immune responses and subsequently the development of a severe disease. Therefore, these epitopes are potential targets for the development of a new class of antiviral products, DENV entry inhibitors. Inhibition of virus attachment is a valuable antiviral strategy because it forms the first barrier to block infection. Several fusion inhibitors, glycosidase inhibitors and heparin mimetics have been described to inhibit DENV entry in the host cell. Here, specific molecules, the carbohydrate-binding agents (CBAs), preventing the interaction between the host and the N-glycans present on the DENV envelope are discussed.
4.1. Carbohydrate-binding agents (CBAs)
The CBAs form a large group of natural proteins, peptides and even synthetic agents that can interact with glycosylated proteins. CBAs can be isolated from different organisms: algae, prokaryotes, fungi, plants, invertebrates and vertebrates (such as DC-SIGN and L-SIGN) [76,77]. Each CBA will interact in a specific way with monosaccharides, such as mannose, fucose, glucose, N-acetylglucosamine, galactose, N-acetylgalactosamine or sialic acid residues present in the backbone of N-glycan structures. Because a lot of enveloped viruses are glycosylated at the viral surface, such as HIV, HCV and DENV (Figure 5), CBAs could interact with the glycosylated envelope of the virus and subsequently prevent viral entry into the host cell [78,79]. Previously, antiviral activity against HIV and HCV [78-80] was demonstrated of several CBAs isolated from plants (plant lectins) and algae specifically binding mannose and N-acetylglucosamine residues.
Here, we focus on the antiviral activity of three plant lectins,
Previously, concanavalin A (Con A), isolated from the Jack bean, binding to mannose residues and wheat germ agglutinin binding to N-acetylglucosamine (Glc-NAc) residues, were shown to reduce DENV infection
4.2. Broad antiviral activity of CBAs against DENV
Because DC-SIGN interacts carbohydrate-dependent with DENV, the antiviral activity of the three plant lectins, HHA, GNA and UDA, recognizing monosaccharides present in the backbone of N-glycans on the DENV E-protein, was evaluated. A consistent dose-dependent antiviral activity was observed in DC-SIGN transfected Raji cells against DENV-2 analyzed by flow cytometry (detecting the presence of DENV Ag) and RT-qPCR (detecting viral RNA in the supernatants) [42].
Next, the antiviral potency of the three plant lectins was determined against all four serotypes of DENV, of which DENV-1 and DENV-4 are low-passage clinical virus isolates, in both Raji/DC-SIGN+ cells and in primary immature MDDC. The use of MDDC has much more clinical relevance than using a transfected cell line. MDDC resemble DC in the skin [83] and mimic an
When DENV is captured by DC, a maturation and activation process occurs. DC require downregulation of C-type lectin receptors [85], upregulation of costimulatory molecules, chemokine receptors and enhancement of their APC function to migrate to the nodal T-cell areas and to activate the immune system [86]. Cytokines implicated in vascular leakage are produced, the complement system becomes activated and virus-induced antibodies can cause DHF via binding to Fc-receptors. Several research groups demonstrated maturation of DC induced by DENV infection [87,88]. Some groups made segregation in the DC population after DENV infection, the infected DC and the uninfected bystander cells. They found that bystander DC, in contrast to infected DC, upregulate the cell surface expression of costimulatory molecules, HLA and maturation molecules. This activation is induced by TNF-α and IFN-α secreted by DENV-infected DC [40,89,90]. Instead, Alen
However, since plant lectins are expensive to produce and not orally bioavailable, the search for non-peptidic small molecules is necessary. PRM-S, a highly soluble non-peptidic small-size carbohydrate-binding antibiotic is a potential new lead compound in HIV therapy, since PRM-S efficiently inhibits HIV replication and prevents capture of HIV to DC-SIGN+ cells [91]. PRM-S also inhibited dose-dependently DENV-2 replication in MDDC but had only a weak antiviral activity in Raji/DC-SIGN+ cells [61]. Actinohivin (AH), a small prokaryotic peptidic lectin containing 114 amino acids, exhibits also anti-HIV-1 activity by recognizing high-mannose-type glycans on the viral envelope [92]. Although DENV has high mannose-type glycans on the E-protein, there was no antiviral activity of AH against DENV infection. Other CBAs such as microvirin, griffithsin and Banlec have been shown to exhibit potent activity against HIV replication [93-95], but these CBAs did not show antiviral activity against DENV. Previously, it has been shown that the CBAs HHA, GNA and UDA also target the N-glycans of other viruses, such as HIV, HCV [79] and HCMV [80]. This indicates that the CBAs can be used as broad-spectrum antiviral agents against various classes of glycosylated enveloped viruses. Although, the three plant lectins did not act inhibitory against parainfluenza-3, vesicular stomatitis virus, respiratory syncytial virus or herpes simplex virus [79]. Together, these data indicate a unique carbohydrate-specificity, and thus also a specific profile of antiviral activity of the CBAs.
4.3. Molecular target of the CBAs on DENV
It was demonstrated in time of drug addition assays that the mannose binding lectin HHA prevents DENV-2 binding to the host cell and acts less efficiently when the virus had already attached to the host cell. It was shown that HHA interacts with DENV and not with cellular membrane proteins such as DC-SIGN on the target cell. The potency of HHA to inhibit attachment of DENV to Raji/DC-SIGN+ cells is comparable to its inhibitory activity of the capture of HIV and HCV to Raji/DC-SIGN+ cells [79]. CBAs could thus be considered as unique prophylactic agents of DENV infection.
To identify the molecular target of the CBAs on DENV, a resistant DENV to HHA was generated in the mosquito cell line C6/36 by Alen
There are some contradictions in terms of necessity of glycosylation of Asn67 and Asn153 during DENV viral progeny. Johnson
The glycosylation at Asn67 is demonstrated to be essential for infection of monocyte-derived dendritic cells (MDDC), indicating an interaction between DC-SIGN and the glycan at Asn67 [96,106]. Also the HHAres DENV was not able to infect efficiently DC-SIGN+ cells or cells that express the DC-SIGN-related liver-specific receptor L-SIGN. Interestingly, MDDC are also not susceptible for HHAres DENV infection, indicating the importance of the DC-SIGN-mediated DENV infection in MDDC. Moreover, cells of the hematopoietic origin, such as DC, are described to be necessary for DENV pathogenesis [84]. If the CBA resistant DENV in not able to infect DC anymore, it can be stated that the CBAs interfere with a physiologically highly relevant target. DC-SIGN is postulated as the most important DENV entry receptor until now. The entry process of DENV in Vero, Huh-7, BHK-21 and C6/36 cell lines is DC-SIGN-independent and also carbohydrate-independent. Indeed, HHAres DENV can efficiently enter and replicate in these cell lines. HHAres DENV lacking both N-glycans on the envelope E-glycoprotein is able to replicate efficiently in mammalian cells, with the exception of DC-SIGN+ cells.
The HHAres virus was used as a tool to identify the antiviral target of other classes of compounds as it could replicate in human liver Huh-7 cells. The use of Huh-7 cells has much more clinical relevance than using monkey (Vero) or hamster (BHK) kidney cells. The HHAres DENV was found cross-resistant to GNA, that recognizes like HHA, -1,3 mannose residues. UDA, which recognizes mainly the N-acetylglucosamine residues of the N-glycans, also lacked antiviral activity against HHAres DENV in Huh-7 cells. This indicates that the entire backbone of the N-glycan is deleted. Likewise, pradimicin-S (PRM-S), a small-size -1,2-mannose-specific CBA, was also unable to inhibit HHAres DENV. This demonstrates that PRM-S targets also the N-glycans on the DENV envelope. In contrast, ribavirin (RBV), a nucleoside analogue and inhibitor of cellular purine synthesis [74], retained as expected wild-type antiviral activity against HHAres DENV. This argues against that there would be compensatory mutations in the non-structural proteins of DENV which are responsible for an overall enhanced replication of the viral genome [107,108]. SA-17, a novel doxorubicine analogue that inhibits the DENV entry process [109], was equipotent against WT and HHAres DENV. The SA-17 compound is predicted to interact with the hydrophobic binding pocket of the E-glycoprotein which is independent from the N-glycosylation state of the E-glycoprotein [109]. These data confirm the molecular docking experiments of SA-17.
Generally, the function of glycosylation on surface proteins is proper folding of the protein, trafficking in the endoplasmic reticulum, interaction with receptors and influencing virus immunogenicity [110]. Virions produced in the mosquito vector and human host may have structurally different N-linked glycans, because the glycosylation patterns are fundamentally different [101,111]. N-glycosylation in mammalian cells is often of the complex-type because a lot of different processing enzymes could add a diversity of monosaccharides. Glycans produced in insect cells are far less complex, because of less diversity in processing enzymes and usually contain more high-mannose and pauci-mannose-type glycans. DC-SIGN can distinguish between mosquito- and mammalian cell-derived alphaviruses [112] and West Nile virus [68], resulting in a more efficient infection by a mosquito-derived virus, but this was not the case for DENV [101].
Although the CBAs HHA and GNA are not mitogenic and not toxic to mice when administered intravenously [113], caution must be taken in the development of the CBAs to use as antiviral drug in the clinic. First, the natural plant lectins are expensive to produce and hard to scale-up, but efforts have been made to express CBAs in commensal bacteria which provide an easy production process of this class of agents. Second, there can be a systemic reaction against the lectins such as in food allergies against peanut lectin or banana lectin [114,115]. Third, the CBAs can recognize aspecifically cellular glycans and could interfere with host cellular processes. But, DENV glycosylation is of the high-mannose or pauci-mannose type, which is only rare on mammalian proteins. The synthetic production of small non-peptidic molecules, such as PRM-S, with CBA-like activity, could overcome the pharmacological problems of the plant lectins. Therefore, PRM-S forms a potential lead candidate in the development of more potent and specific DENV entry inhibitors.
5. Conclusion
In conclusion, besides active vector control in tropical and subtropical regions, there is an urgent need for antiviral treatment to protect half of the world’s population against severe DENV infections. DC-SIGN is thought to be the most important DENV receptor and that the DC-SIGN-DENV envelope protein interaction is an excellent target for viral entry inhibitors such as the CBAs. Resistance against HHA forces the virus to delete its N-glycans and subsequently this mutant virus is not able anymore to infect its most important target cells. Thus the CBAs act in two different ways: prevention of viral entry by directly binding N-glycans on the viral envelope and indirectly forcing the virus to delete its N-glycans and loose the capability to infect DC. The plant lectins provided more insight into the entry pathway of the virus into the host cell. Hopefully some of these future derivatives with a comparable mode of action will reach clinical trials in the near future.
Acknowledgement
We are grateful to S. Claes, B. Provinciael, E. Van Kerckhove and E. Fonteyn for excellent technical assistance. This work was supported by the FWO (G-485-08N and G.0528.12N), the KU Leuven (PF/10/018 and GOA/10/014) and the Dormeur Investment Service Ltd.
References
- 1.
Holmes EC, Twiddy SS 2003 The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol3 19 28 - 2.
Mackenzie JS, Gubler DJ, Petersen LR 2004 Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98 S109. - 3.
Halstead SB 2008 Dengue virus- Mosquito interactions. Annu Rev Entomol53 273 291 - 4.
Gubler DJ 1998 Dengue and dengue hemorrhagic fever. Clin Microbiol Rev11 480 496 - 5.
Halstead SB 2007 Dengue. Lancet370 1644 1652 - 6. Monath TP (
1994 ) Dengue- the risk to developed and developing countries. Proc Natl Acad Sci U S A 91: 2395-2400. - 7.
Whitehead SS, Blaney JE, Durbin AP, Murphy BR 2007 Prospects for a dengue virus vaccine. Nat Rev Microbiol5 518 528 - 8.
Walker T. Johnson P. H. Moreira L. A. Iturbe-Ormaetxe I. Frentiu F. D. Mc Meniman C. J. et al. 2011 The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature476 450 453 - 9.
AA Hoffmann Montgomery. B. L. Popovici J. Iturbe-Ormaetxe I. Johnson P. H. Muzzi F. et al. 2011 Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature476 454 457 - 10.
Mairuhu A. T. A. Wagenaar J. Brandjes D. P. M. van Gorp E. C. M. 2004 Dengue: an arthropod-borne disease of global importance. Eur J Clin Microbiol Infect Dis23 425 433 - 11.
Rigau-Pérez J. G. Clark G. G. Gubler D. J. Reiter P. Sanders R. J. Vorndam A. V. 1998 Dengue and dengue haemorrhagic fever. Lancet352 971 977 - 12.
Solomon T. Mallewa M. 2001 Dengue and other emerging flaviviruses. J Infect42 104 115 - 13.
Halstead SB 1988 Pathogenesis of dengue: challenges to molecular biology. Science239 476 481 - 14.
Takada A. Kawaoka Y. 2003 Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol13 387 398 - 15.
Kliks S. C. Nimmanitya S. Nisalak A. DS Burke 1988 Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg38 411 419 - 16.
Halstead SB 1979 In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis140 527 533 - 17.
Wu S. J. L. Grouard-Vogel G. Sun W. Mascola J. R. Brachtel E. Putvatana R. et al. 2000 Human skin Langerhans cells are targets of dengue virus infection. Nat Med6 816 820 - 18.
Kou Z. Quinn M. Chen H. Y. Rodrigo W. W. Rose R. C. Schlesinger J. J. et al. 2008 Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol80 134 146 - 19.
Kuhn R. J. Zhang W. Rossmann M. G. Pletnev S. V. Corver J. Lenches E. et al. 2002 Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion. Cell108 717 725 - 20.
Acosta E. G. Castilla V. Damonte E. B. 2008 Functional entry of dengue virus into Aedes albopictus mosquito cells is dependent on clathrin-mediated endocytosis. J Gen Virol89 474 484 - 21.
van der Schaar H. M. MJ Rust Chen. C. van der Ende-Metselaar H. Wilschut J. Zhuang X. W. et al. 2008 Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. Plos Pathog 4: e1000244. - 22.
Chu JJH, Ng ML 2004 Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol78 10543 10555 - 23.
Nawa M. Takasaki T. Yamada K. Kurane I. Akatsuka T. 2003 Interference in Japanese encephalitis virus infection of vero cells by a cationic amphiphilic drug, chlorpromazine. J Gen Virol84 1737 1741 - 24.
Acosta E. G. Castilla V. Damonte E. B. 2009 Alternative infectious entry pathways for dengue virus serotypes into mammalian cells. Cell Microbiol11 1533 1549 - 25.
Modis Y. Ogata S. Clements D. Harrison S. C. 2004 Structure of the dengue virus envelope protein after membrane fusion. Nature427 313 319 - 26.
Stiasny K. Fritz R. Pangerl K. Heinz F. X. 2009 Molecular mechanisms of flavivirus membrane fusion. Amino Acids41 1159 1163 - 27.
Martin C. S. S. Liu C. Y. Kielian M. 2009 Dealing with low pH: entry and exit of alphaviruses and flaviviruses. Trends Microbiol17 514 521 - 28.
Zhang Y. Zhang W. Ogata S. Clements D. Strauss J. H. Baker T. S. et al. 2004 Conformational changes of the flavivirus E glycoprotein. Structure12 1607 1618 - 29.
Perera R. Khaliq M. Kuhn R. J. 2008 Closing the door on flaviviruses: Entry as a target for antiviral drug design. Antiviral Res80 11 22 - 30.
Modis Y. Ogata S. Clements D. Harrison S. C. 2003 A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A100 6986 6991 - 31.
Rey F. A. Heinz F. X. Mandl C. Kunz C. Harrison S. C. 1995 The envelope glycoprotein from tick-borne encephalitis virus at 2 angstrom resolution. Nature375 291 298 - 32.
Crill WD, Roehrig JT 2001 Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol75 7769 7773 - 33.
Rajamanonmani R. Nkenfou C. Clancy P. Yau Y. H. Shochat S. G. Sukupolvi-Petty S. et al. 2009 On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol90 799 809 - 34.
Scherret JH, Mackenzie JS, Khromykh AA, Hall RA 2001 Biological significance of glycosylation of the envelope protein of Kunjin virus. Ann N Y Acad Sci951 361 363 - 35.
Halstead SB, O’rourke EJ, Allison AC 1977 Dengue viruses and mononuclear phagocytes.II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med146 218 229 - 36.
Durbin A. P. MJ Vargas Wanionek. K. Hammond S. N. Gordon A. Rocha C. et al. 2008 Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology376 429 435 - 37.
Kliks S. C. Nisalak A. Brandt W. E. Wahl L. DS Burke 1989 Antibody-dependent enhancement of dengue virus growth in human-monocytes as a risk factor for dengue hemorrhagic-fever. Am J Trop Med Hyg40 444 451 - 38.
Taweechaisupapong S. Sriurairatana S. Angsubhakorn S. Yoksan S. MM Khin Sahaphong. S. et al. 1996 Langerhans cell density and serological changes following intradermal immunisation of mice with dengue 2 virus. J Med Microbiol45 138 145 - 39.
Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW et al. 2001 Infection of human dendritic cells by Dengue virus causes cell maturation and cytokine production. J Immunol166 1499 1506 - 40.
Libraty D. H. Pichyangkul S. Ajariyakhajorn C. Endy T. P. Ennis F. A. 2001 Human dendritic cells are activated by dengue virus infection: Enhancement by gamma interferon and implications for disease pathogenesis. J Virol75 3501 3508 - 41.
Marovich M. Grouard-Vogel G. Louder M. Eller M. Sun W. Wu S. J. et al. 2001 Human dendritic cells as targets of dengue virus infection. J Invest Dermatol6 219 224 - 42.
Alen M. M. F. Kaptein S. J. F. De Burghgraeve T. Balzarini J. Neyts J. Schols D. 2009 Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology387 67 75 - 43.
Lozach P. Y. Burleigh L. Staropoli I. Navarro-Sanchez E. Harriague J. Virelizier J. L. et al. 2005 Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem280 23698 23708 - 44.
Navarro-Sanchez E. Altmeyer R. Amara A. Schwartz O. Fieschi F. Virelizier J. L. et al. 2003 Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. Embo Rep4 723 728 - 45.
Tassaneetrithep B. Burgess T. H. Granelli-Piperno A. Trumpfherer C. Finke J. Sun W. et al. 2003 DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med197 823 829 - 46.
van Kooyk Y. Geijtenbeek T. B. H. 2003 DC-SIGN: Escape mechanism for pathogens. Nat Rev Immunol3 697 709 - 47.
Mitchell D. A. Fadden A. J. Drickamer K. 2001 A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR- Subunit organization and binding to multivalent ligands. J Biol Chem276 28939 28945 - 48.
Appelmelk B. J. van Die I. van Vliet S. J. Vandenbroucke-Grauls C. M. J. E. Geijtenbeek T. B. H. van Kooyk Y. 2003 Cutting edge: Carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol170 1635 1639 - 49.
294 2163 2166 Feinberg H, Mitchell DA, Drickamer K, Weis WI (2001) Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294: 2163-2166 - 50.
Geijtenbeek T. B. H. DS Kwon Torensma. R. van Vliet S. J. van Duijnhoven G. C. F. Middel J. et al. 2000 DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell100 587 597 - 51.
Pöhlmann S. Zhang J. Baribaud F. Chen Z. W. Leslie G. Lin G. et al. 2003 Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol77 4070 4080 - 52.
Marzi A. Möller P. Hanna S. L. Harrer T. Eisemann J. Steinkasserer A. et al. 2007 Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule3 grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 196 (Suppl 2): S237-S246. - 53.
Geijtenbeek T. B. H. Krooshoop D. J. E. B. Bleijs D. A. van Vliet S. J. van Duijnhoven G. C. F. Grabovsky V. et al. 2000 DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol1 353 357 - 54.
Banchereau J. Steinman R. M. 1998 Dendritic cells and the control of immunity. Nature392 245 252 - 55.
Nair M. P. N. Reynolds J. L. Mahajan S. D. Schwartz S. A. Aalinkeel R. Bindukumar B. et al. 2005 RNAi-directed inhibition of DC-SIGN by dendritic cells: Prospects for HIV-1 therapy. AAPS J 7: E572 E578. - 56.
Dakappagari N. Maruyama T. Renshaw M. Tacken P. Figdor C. Torensma R. et al. 2006 Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J Immunol176 426 440 - 57.
Anderluh M. Jug G. Svajger U. Obermajer N. 2012 DC-SIGN antagonists, a potential new class of anti-infectives. Curr Med Chem19 992 1007 - 58.
Chen YC, Wang SY 2002 Activation of terminally differentiated human monocytes/macrophages by dengue virus: Productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol76 9877 9887 - 59.
Miller J. L. Dewet B. J. M. Martinez-Pomares L. Radcliffe C. M. Dwek R. A. Rudd P. M. et al. 2008 The mannose receptor mediates dengue virus infection of macrophages. Plos Pathog 4: e17. - 60.
Kwan W. H. Helt A. M. Maranon C. Barbaroux J. B. Hosmalin A. Harris E. et al. 2005 Dendritic cell precursors are permissive to dengue virus and human immunodeficiency virus infection. J Virol79 7291 7299 - 61.
Alen M. M. F. De Burghgraeve T. Kaptein S. J. F. Balzarini J. Neyts J. Schols D. 2011 Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. Plos One 6: e21658. - 62.
de Witte L. Bobardt M. Chatterji U. Degeest G. David G. Geijtenbeek T. B. et al. 2007 Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc Natl Acad Sci U S A104 19464 19469 - 63.
AA Lambert Gilbert. C. Richard M. Beaulieu A. D. MJ Tremblay 2008 The C-type lectin surface receptor DICIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood112 1299 1307 - 64.
Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY et al. 2008 CLEC5A is critical for dengue-virus-induced lethal disease. Nature453 672 676 - 65.
AA Watson Lebedev. BA Hall-May Fenton. Vagin A. E. AA Dejnirattisai W. et al. 2011 Structural flexibility of the macrophage dengue virus receptor CLEC5A implications for ligand binding and signaling. J Biol Chem286 24208 24218 - 66.
Bashirova AA, Geijtenbeek TBH, van Duijnhoven GCF, van Vliet SJ, Eilering JBG, Martin MP et al. 2001 A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med193 671 678 - 67.
Pöhlmann S. Soilleux E. J. Baribaud F. Leslie G. J. Morris L. S. Trowsdale J. et al. 2001 DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A98 2670 2675 - 68.
Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, Pierson TC 2006 West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol80 1290 1301 - 69.
Zellweger R. M. Prestwood T. R. Shresta S. 2010 Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe7 128 139 - 70.
Avirutnan P. Malasit P. Seliger B. Bhakdi S. Husmann M. 1998 Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol161 6338 6346 - 71.
Seneviratne SL, Malavige GN, de Silva HJ 2006 Pathogenesis of liver involvement during dengue viral infections. Trans R Soc Trop Med Hyg100 608 614 - 72.
Murrell S. Wu S. C. Butler M. 2011 Review of dengue virus and the development of a vaccine. Biotechnol Adv29 239 247 - 73.
Murphy BR, Whitehead SS 2011 Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol29 587 619 - 74.
Leyssen P. De Clercq E. Neyts J. 2008 Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res78 9 25 - 75.
Sampath A. Padmanabhan R. 2009 Molecular targets for flavivirus drug discovery. Antiviral Res81 6 15 - 76.
Balzarini J. 2006 Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res71 237 247 - 77.
François K. O. Balzarini J. 2010 Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev. - 78.
Balzarini J. Van Herrewege Y. Vermeire K. Vanham G. Schols D. 2007 Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol71 3 11 - 79.
Bertaux C. Daelemans D. Meertens L. Cormier E. G. Reinus J. F. Peumans W. J. et al. 2007 Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology366 40 50 - 80.
Balzarini J. Schols D. Neyts J. Van Damme E. Peumans W. De Clercq E. 1991 Alpha-(1-3)-D-mannose-specific and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother35 410 416 - 81.
Harata K. Muraki M. 2000 Crystal structures of Urtica dioica agglutinin and its complex with tri-N-acetylchitotriose. Journal of Molecular Biology297 673 681 - 82.
Hung SL, Lee PL, Chen HW, Chen LK, Kao CL, King CC 1999 Analysis of the steps involved in dengue virus entry into host cells. Virology257 156 167 - 83.
Grassi F. Dezutter-Dambuyant C. Mc Ilroy D. Jacquet C. Yoneda K. Imamura S. et al. 1998 Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. J Leukoc Biol64 484 493 - 84.
Pham AM, Langlois RA, TenOever BR 2012 Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination. Plos Pathog 8: e1002465. - 85.
Relloso M. Puig-Kröger A. Pello O. M. Rodriguez-Fernandez J. L. de la Rosa G. Longo N. et al. 2002 DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents. J Immunol168 2634 2643 - 86.
Tacken P. J. de Vries I. J. M. Torensma R. Figdor C. G. 2007 Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol7 790 802 - 87.
Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW et al. 2001 Infection of human dendritic cells by Dengue virus causes cell maturation and cytokine production. J Immunol166 1499 1506 - 88.
Sun P. Fernandez S. MA Marovich Palmer. D. R. Celluzzi C. M. Boonnak K. et al. 2009 Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology383 207 215 - 89.
Dejnirattisai W. Duangchinda T. Lin C. L. S. Vasanawathana S. Jones M. Jacobs M. et al. 2008 A complex interplay among virus, dendritic cells, T cells, and cytokines in Dengue virus infections. J Immunol181 5865 5874 - 90.
Palmer D. R. Sun P. F. Celluzzi C. Bisbing J. Pang S. N. Sun W. et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol2005 79 2432 2439 - 91.
Balzarini J. François K. O. Van Laethem K. Hoorelbeke B. Renders M. Auwerx J. et al. 2010 Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob Agents Chemother54 1425 1435 - 92.
Hoorelbeke B. Huskens D. Férir G. François K. O. Takahashi A. Van Laethem K. et al. 2010 Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother54 3287 3301 - 93.
Alexandre K. B. Gray E. S. Mufhandu H. Mc Mahon J. B. Chakauya E. O’Keefe B. R. et al. 2012 The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology423 175 186 - 94.
Huskens D. Férir G. Vermeire K. Kehr J. C. Balzarini J. Dittmann E. et al. 2010 Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem285 24845 24854 - 95.
Swanson MD, Winter HC, Goldstein IJ, Markovitz DM 2010 A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem285 8646 8655 - 96.
Mondotte J. A. Lozach P. Y. Amara A. Gamarnik A. V. 2007 Essential role of dengue virus envelope protein N-glycosylation at asparagine-67 during viral propagation. J Virol81 7136 7148 - 97.
Ploegh H. Neefjes J. J. 1990 Protein glycosylation. Curr Opin Cell Biol2 1125 1130 - 98.
Pugachev K. V. Guirakhoo F. Ocran S. W. Mitchell F. Parsons M. Penal C. et al. 2004 High fidelity of yellow fever virus RNA polymerase. J Virol78 1032 1038 - 99.
Thai K. T. D. Henn M. R. Zody M. C. Tricou V. Nguyet N. M. Charlebois P. et al. 2012 High-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections. J Virol86 835 843 - 100.
Johnson A. J. Guirakhoo F. Roehrig J. T. 1994 The envelope glycoproteins of dengue-1 and dengue-2 viruses grown in mosquito cells differ in their utilization of potential glycosylation sites. Virology203 241 249 - 101.
Hacker K. White L. de Silva A. M. N-Linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol2009 90 2097 2106 - 102.
Lee E. Leang S. K. Davidson A. Lobigs M. 2010 Both E protein glycans adversely affect dengue virus infectivity but are beneficial for virion release. J Virol84 5171 5180 - 103.
Guirakhoo F. Hunt A. R. Lewis J. G. Roehrig J. T. 1993 Selection and partial characterization of dengue-2 virus mutants that induce fusion at elevated pH. Virology194 219 223 - 104.
Lee E. Weir R. C. Dalgarno L. 1997 Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein. Virology232 281 290 - 105.
Bryant J. E. Calvert A. E. Mesesan K. Crabtree M. B. Volpe K. E. Silengo S. et al. 2007 Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes. Virology366 415 423 - 106.
Pokidysheva E. Zhang Y. Battisti A. J. Bator-Kelly C. M. Chipman P. R. CA Xiao et. al 2006 Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell124 485 493 - 107.
Wang Q. Y. Bushell S. Qing M. Xu H. Y. Bonavia A. Nunes S. et al. 2011 Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol85 6548 6556 - 108.
Xie X. Wang Q. Y. Xu H. Y. Qing M. Kramer L. Yuan Z. et al. 2011 Inhibition of dengue virus by targeting viral NS4B protein. J Virol85 11183 11195 - 109.
Kaptein S. J. F. De Burghgraeve T. Froeyen M. Pastorino B. Alen M. M. F. Mondotte J. A. et al. 2010 A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob Agents Chemother54 5269 5280 - 110.
Vigerust DJ, Shepherd VL 2007 Virus glycosylation: role in virulence and immune interactions. Trends Microbiol15 211 218 - 111.
Rogers K. M. Heise M. 2009 Modulation of cellular tropism and innate antiviral response by viral glycans. J Innate Immun1 405 412 - 112.
Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD 2003 DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell- and mammalian cell-derived viruses. J Virol77 12022 12032 - 113.
Balzarini J. Hatse S. Vermeire K. Princen K. Aquaro S. Perno C. F. et al. 2004 Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother48 3858 3870 - 114.
Rougé P. Culerrier R. Granier C. Rancé F. Barre A. Characterization of IgE-binding epitopes of peanut (Arachis hypogaea) PNA lectin allergen cross-reacting with other structurally related legume lectins. Molecular Immunology2010 47 2359 2366 - 115.
Sanchez-Monge R. Blanco C. Diaz-Perales A. Collada C. Carrillo T. Aragoncillo C. et al. 1999 Isolation and characterization of major banana allergens: identification as fruit class I chitinases. Clin Exp Allergy29 673 680